WHO validates Gambia for having eliminated trachoma as a public health problem who.int - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from who.int Daily Mail and Mail on Sunday newspapers.
Date Time
WHO validates Gambia for having eliminated trachoma as a public health problem
The World Health Organization (WHO) has validated Gambia for having eliminating trachoma as a public health problem, making it the second country in WHO’s African Region to achieve this milestone.
“This is a great step towards the 2030 goals set by the recently launched 2021–2030 road map for neglected tropical diseases” said Dr Ren Minghui, WHO Assistant Director-General Universal Health Coverage/Communicable and Noncommunicable Diseases. “So far this year, Gambia has become the second country, after Côte d’Ivoire, to eliminate a neglected tropical disease.”
Gambia’s success in eliminating trachoma is largely attributed to strong collaboration with partner organizations to implement WHO’s SAFE strategy
Increased access to testing, treatment has reduced hepatitis C in low- and middle-income countries
Many low- and middle-income countries have reduced suffering from hepatitis C, thanks to increased access to testing and treatment. Some achieved a 20-fold increase in the number of people treated with safe and effective direct-acting retroviral drugs between 2015 and 2018, according to the
Global progress report on accelerating access to hepatitis C diagnostics and treatment, released by WHO today.
A drop in prices underpins this success
Low- and middle-income countries can now aim to achieve a price as low as US$ 60 per patient for a 12-week course of treatment with WHO-prequalified generic sofosbuvir and daclatasvir. Prices offered by suppliers of WHO-prequalified HCV rapid diagnostic tests ranged between US$ 1 and US$ 8 per test.
Novartis renews partnership with WHO to eradicate leprosy
Novartis renews partnership with WHO to eradicate leprosy
01 February 2021 | News The five-year extension of the partnership will see Novartis continue to donate multi-drug therapy (MDT) medicines to treat leprosy up to the end of 2025
Source credit: Shutterstock
A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 – will see Novartis continue to donate multi-drug therapy (MDT) medicines to treat leprosy up to the end of 2025. Leprosy can be cured and prevented. With a comprehensive approach, we can see the end of leprosy,” said Dr Lutz Hegemann, Chief Operating Officer, Global Health, Novartis. “By supplying this treatment free of charge to WHO over the last 20 years we have helped over seven million people be cured of leprosy. We l
Visit Novartis Global Health on Twitter and Linkedin.
Friday, January 29, 2021 - 1:15am
CONTENT: Press Release
BASEL, SWITZERLAND, January 29, 2021 /3BL Media/ A renewed partnership agreement signed by Novartis and the World Health Organization (WHO) will drive the global push towards making leprosy history. The five-year extension of the partnership – which was first signed in 2000 – will see Novartis continue to donate multidrug therapy (MDT) medicines to treat leprosy up to the end of 2025.
Widespread use of MDT has led to a 95% reduction in leprosy prevalence world-wide since its introduction the 1980s, though more than 200,000 cases are still seen every year.
1 Despite the huge impact of MDT, governments, donors, civil society and the private sector will need to collaborate on deploying additional tools if the world is to get to zero leprosy.